SCHEMBL30457510

SCHEMBL30457510

CC(C)(CNC(=O)c1ncc(-c2cccc(OCc3ccc(Cl)cc3)c2)cc1O)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 16/20 0.55
EGLN3 Q9H6Z9 4/20 0.55
VEGFA P15692 4/20 0.55
FLT1 P17948 4/20 0.55
TET3 O43151 1/20 0.52
BBOX1 O75936 1/20 0.52
ASPH Q12797 1/20 0.52
TET2 Q6N021 1/20 0.52
KDM8 Q8N371 1/20 0.52
OGFOD1 Q8N543 1/20 0.52
TET1 Q8NFU7 1/20 0.52
HIF1AN Q9NWT6 1/20 0.52
EGLN2 Q96KS0 6/20 0.49
SMPD1 P17405 1/20 0.45
NR4A2 P43354 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25274490 1.00 EGLN1 (0.55) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL25282012 0.91 EGLN1 (0.53) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL30458038 0.91 EGLN1 (0.53) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL30457430 0.90 EGLN1 (0.59) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL25276548 0.90 EGLN1 (0.54) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL30458209 0.90 EGLN1 (0.54) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL25232892 0.90 EGLN1 (0.59) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL25234857 0.90 EGLN1 (0.58) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL30457918 0.90 EGLN1 (0.58) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL25274392 0.86 EGLN1 (0.53) EGLN1EGLN3VEGFAFLT1TET3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4447963-A1 SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2024-10-23 EP disclosed
CN-118715015-A Selective PHD1 inhibitor compounds, compositions and methods of use 阿克比治疗有限公司 2024-09-27 CN disclosed
WO-2023111990-A1 SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-06-22 WO disclosed